Quick Answer: Clomid vs Enclomiphene
Clomid (clomiphene citrate) is a racemic mixture of two isomers, while enclomiphene is the purified trans-isomer only. Both raise testosterone through the same SERM mechanism at the hypothalamus, but they differ in side effect profile, half-life, and estrogenic activity. Enclomiphene avoids the estrogenic effects of zuclomiphene (Clomid’s other isomer), which may reduce mood-related side effects and visual disturbances.
- Clomid contains both enclomiphene (anti-estrogenic, raises T) and zuclomiphene (partial estrogen agonist, long half-life). Decades of clinical data. Approved for female infertility.
- Enclomiphene is the isolated active isomer only. Cleaner pharmacology. Shorter half-life. Fewer estrogenic side effects in trials. Not yet FDA-approved as a standalone drug.
- Both raise testosterone by 200-400 ng/dL on average in hypogonadal men while preserving fertility and spermatogenesis.
- Enclomiphene may be preferable for men sensitive to estrogenic side effects, but Clomid has a far longer safety track record.
Introduction: The Same Molecule, Two Approaches
Clomiphene citrate (Clomid) has been used in clinical medicine since the 1960s and has become one of the most studied alternatives to testosterone replacement therapy (TRT) for men with secondary hypogonadism. However, Clomid is a racemic mixture. It contains two stereoisomers in roughly equal proportions: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). These two isomers have distinct pharmacological properties, and the emergence of purified enclomiphene as a separate compound has created an important debate in men’s health.
Understanding the difference matters. Enclomiphene is responsible for most of Clomid’s testosterone-raising effects, while zuclomiphene has partial estrogen agonist activity that may contribute to side effects some men experience on Clomid. This comparison examines the pharmacology, clinical evidence, side effect profiles, and practical considerations for each approach based on published research through 2025.
Pharmacology: Two Isomers, Different Properties
What Is a Racemic Mixture?
A racemic mixture contains equal amounts of two mirror-image molecules (stereoisomers) that have the same chemical formula but different three-dimensional arrangements. In the case of clomiphene citrate, the two isomers are enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). While they share the same atoms, their biological activities differ significantly because receptors in the body are stereospecific. They respond differently to each spatial configuration.
| Property | Enclomiphene (trans) | Zuclomiphene (cis) |
|---|---|---|
| Estrogen receptor activity | Predominantly antagonist (anti-estrogenic) | Mixed agonist/antagonist (partial estrogen agonist) |
| Half-life | ~10 hours | ~30 days (accumulates with repeated dosing) |
| Effect on LH/FSH | Strong stimulation (blocks estrogen negative feedback) | Weak or absent stimulation |
| Testosterone effect | Primary driver of testosterone increase | Minimal direct testosterone effect |
| Estrogenic side effects | Minimal (antagonist profile) | Yes (hot flashes, mood changes, visual disturbances) |
| Accumulation | Reaches steady state in ~3 days | Accumulates over weeks due to 30-day half-life |
The key insight: when a man takes Clomid, the enclomiphene component does most of the therapeutic work (blocking estrogen feedback, raising LH, raising testosterone). But the zuclomiphene component accumulates over time due to its extremely long half-life of approximately 30 days. After several weeks of Clomid use, zuclomiphene concentrations can exceed enclomiphene concentrations by a significant margin. This accumulated zuclomiphene may contribute to estrogenic side effects that some men report with chronic Clomid use (Wiehle et al., 2014, Fertility and Sterility; Kaminetsky et al., 2013, Journal of Urology).
Mechanism of Action
Shared SERM Mechanism
Both Clomid and enclomiphene work by blocking estrogen receptors at the hypothalamus. Under normal conditions, estradiol (E2) provides negative feedback to the hypothalamus, suppressing gonadotropin-releasing hormone (GnRH) pulse frequency. When a SERM blocks this feedback, GnRH pulsatility increases, driving the anterior pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells to produce testosterone, while FSH supports spermatogenesis in Sertoli cells (Bhasin et al., 2018, JCEM).
This is the critical advantage over exogenous testosterone (TRT): both Clomid and enclomiphene keep the hypothalamic-pituitary-gonadal (HPG) axis active. TRT shuts it down, which is why TRT typically causes azoospermia or severe oligospermia in men of reproductive age (Samplaski et al., 2014, Fertility and Sterility).
Where They Differ
The difference lies in zuclomiphene. In Clomid, the zuclomiphene isomer acts as a partial estrogen agonist at certain tissues. While it does not fully activate estrogen receptors like estradiol does, its partial agonist activity can produce estrogenic effects in some men, particularly with long-term use as zuclomiphene accumulates. Purified enclomiphene eliminates this variable entirely, providing a cleaner anti-estrogenic signal at the hypothalamus without the confounding agonist activity of zuclomiphene.
Clinical Evidence
Clomid (Racemic Clomiphene Citrate)
Clomid has decades of clinical data supporting its use in men with secondary hypogonadism:
| Study | Population | Dose | Baseline T | Post-Treatment T | Duration |
|---|---|---|---|---|---|
| Katz et al., 2012 | Young hypogonadal men (N=86) | 25-50 mg EOD | ~309 ng/dL | ~642 ng/dL (+108%) | Mean 19 months |
| Guay et al., 2003 | Secondary hypogonadism + ED (N=173) | 25 mg daily | 241 ng/dL | 527 ng/dL (+119%) | 4-6 months |
| Krzastek et al., 2019 | Long-term hypogonadal cohort (N=83) | 25 mg daily | ~250 ng/dL | ~600 ng/dL | Up to 3 years |
| Taylor & Levine, 2010 | Hypogonadal men with infertility | 25-50 mg daily | ~280 ng/dL | ~490 ng/dL | 3+ months |
A systematic review by Huijben et al. (2022, Andrology) evaluated 19 studies and confirmed that racemic clomiphene consistently increases total testosterone, LH, and FSH in hypogonadal men, with most responders reaching mid-normal testosterone levels (500-700 ng/dL). Sperm parameters are generally preserved or improved.
Enclomiphene (Purified Trans-Isomer)
Enclomiphene has been studied in multiple Phase II and Phase III clinical trials, primarily under the brand name Androxal (developed by Repros Therapeutics):
| Study | Population | Dose | Key Findings |
|---|---|---|---|
| Kaminetsky et al., 2013 (ZA-301) | Secondary hypogonadal men (N=73) | 12.5 or 25 mg daily | Both doses raised T into normal range. Sperm counts preserved. Morning T levels normalized in 73% (25 mg) vs 37% (placebo). |
| Wiehle et al., 2014 (ZA-302) | Overweight hypogonadal men (N=48) | 12.5 or 25 mg daily | Significant T increase. Mean T rose from 223 ng/dL to 452 ng/dL (12.5 mg) and 468 ng/dL (25 mg). Sperm counts maintained or improved. |
| Kim et al., 2017 | Open-label extension (N=132) | 12.5 or 25 mg daily | T elevation sustained over 6 months. LH/FSH remained elevated. No serious adverse events. |
The Androxal trials demonstrated that enclomiphene raises testosterone comparably to racemic Clomid, but at lower doses (12.5-25 mg vs 25-50 mg) and potentially with a cleaner side effect profile due to the absence of zuclomiphene accumulation.
Head-to-Head Comparison
| Feature | Clomid (Racemic) | Enclomiphene (Purified) |
|---|---|---|
| Composition | ~62% enclomiphene + ~38% zuclomiphene | 100% enclomiphene (trans-isomer only) |
| Testosterone increase | +100-200% from baseline in most studies | +100-200% from baseline in most studies |
| Typical dose | 25-50 mg daily or every other day | 12.5-25 mg daily |
| Fertility preservation | Yes. LH, FSH, and sperm maintained. | Yes. LH, FSH, and sperm maintained. |
| Estrogenic side effects | Possible (zuclomiphene accumulation): mood changes, hot flashes, visual disturbances | Reduced (no zuclomiphene). Cleaner pharmacological profile. |
| Visual disturbances | Reported in ~1-5% of users. Attributed to zuclomiphene estrogenic agonism. | Rare in Androxal trials. May be lower without zuclomiphene. |
| Half-life (effective) | Complex: enclomiphene ~10h, zuclomiphene ~30 days | ~10 hours. Predictable kinetics. |
| Zuclomiphene accumulation | Yes. Builds over weeks of use. | None. Single isomer. |
| Clinical evidence (men) | Decades. Hundreds of studies. Well-characterized. | Phase II/III trials. Promising but less long-term data. |
| FDA status | Approved for female infertility. Off-label for men. | Not FDA-approved. Androxal received Complete Response Letters (2015, 2016). |
| Availability | Generic, widely available, inexpensive | Available as research compound. No approved pharmaceutical formulation. |
| Cost | Low (generic drug, well-established manufacturing) | Higher (specialty synthesis required) |
Side Effect Profiles: A Closer Look
The side effect differences between Clomid and enclomiphene are primarily attributed to zuclomiphene, the partial estrogen agonist present only in racemic Clomid.
Clomid Side Effects
- Visual disturbances (1-5%): Blurred vision, photophobia, scotomata. The most concerning side effect. Generally reversible upon discontinuation. More likely with higher doses and longer duration. Attributed to zuclomiphene’s estrogenic activity at retinal tissue.
- Mood changes: Some men report emotional lability, irritability, or depressive symptoms. Potentially related to zuclomiphene’s agonist activity at central estrogen receptors.
- Hot flashes: Related to rapid estrogen receptor modulation. Relatively common.
- Gynecomastia (rare): Paradoxical estrogenic stimulation from zuclomiphene at breast tissue. Uncommon at standard male dosing.
- GI disturbance: Nausea, bloating. Generally mild.
Enclomiphene Side Effects
- Headache: Most commonly reported in Androxal trials (mild).
- Hot flashes: Still present (inherent to SERM mechanism) but may be less frequent.
- GI disturbance: Nausea, abdominal discomfort. Similar to Clomid.
- Visual disturbances: Not reported as a significant finding in Androxal trials, though long-term surveillance data is limited.
- Mood effects: Not prominent in trial data. Absence of zuclomiphene may reduce emotional side effects.
The clinical significance: for most men, racemic Clomid is well-tolerated at standard doses (25-50 mg daily or every other day). However, the subset of men who experience mood disturbances, visual symptoms, or feel “estrogenic” on Clomid may benefit from enclomiphene, which removes zuclomiphene from the equation entirely.
The FDA Story: Why Enclomiphene Is Not Approved
Repros Therapeutics developed enclomiphene as Androxal and pursued FDA approval for male secondary hypogonadism. Despite positive Phase III results showing testosterone normalization with preserved sperm counts, the FDA issued Complete Response Letters (CRLs) in both 2015 and 2016. The primary concerns were related to the FDA’s broader skepticism about testosterone-raising therapies at the time (following the 2014 testosterone cardiovascular safety review) and specific issues with the Phase III trial analytics, not fundamental safety or efficacy problems with the molecule (Repros Therapeutics SEC filings, 2016).
Repros eventually discontinued development, and the Androxal program was shelved. Enclomiphene has since become available as a research compound from various suppliers. Several pharmaceutical companies have explored reviving enclomiphene development, but as of 2025, no approved formulation exists in North America.
Practical Considerations for Researchers
When Clomid May Be Preferred
- Established safety record spanning decades
- Generic availability keeps cost low
- Physician familiarity. Most endocrinologists and urologists have clinical experience with Clomid.
- Well-tolerated at standard doses (25-50 mg daily/EOD) in most men
- Pharmaceutical-grade manufacturing with consistent quality
When Enclomiphene May Be Preferred
- Men who experienced mood side effects on racemic Clomid
- Men who developed visual disturbances on Clomid
- Desire for cleaner pharmacokinetics (single isomer, no zuclomiphene accumulation)
- Lower effective dose may be sufficient (12.5-25 mg vs 25-50 mg)
- More predictable washout (10h half-life vs weeks of zuclomiphene clearance)
Frequently Asked Questions
Is enclomiphene the same as Clomid?
Not exactly. Enclomiphene is one of the two isomers found in Clomid. Clomid (clomiphene citrate) contains approximately 62% enclomiphene and 38% zuclomiphene. Purified enclomiphene contains only the trans-isomer, without zuclomiphene. The testosterone-raising mechanism is the same, but the side effect profile differs due to the absence of zuclomiphene.
Does enclomiphene raise testosterone more than Clomid?
Clinical data suggests comparable testosterone increases. Both raise testosterone by approximately 100-200% from baseline in hypogonadal men. Enclomiphene achieves this at lower doses (12.5-25 mg) compared to Clomid (25-50 mg), because it is the purified active isomer without the inactive zuclomiphene diluting the dose.
Why is enclomiphene not FDA approved?
Repros Therapeutics received Complete Response Letters from the FDA in 2015 and 2016 for its Androxal (enclomiphene citrate) application. The FDA’s concerns were primarily related to trial analytics and the broader regulatory climate around testosterone therapies at the time, not fundamental safety issues with enclomiphene itself. Repros discontinued development, and no other company has completed the approval process as of 2025.
Can you switch from Clomid to enclomiphene?
Switching is pharmacologically straightforward since both work through the same SERM mechanism. However, be aware that zuclomiphene from Clomid has a half-life of approximately 30 days, so it may take several weeks for zuclomiphene to fully clear after discontinuing Clomid. During this transition, you are effectively using both compounds until zuclomiphene washes out.
Does enclomiphene preserve fertility like Clomid?
Yes. Both Clomid and enclomiphene preserve fertility by maintaining LH and FSH secretion, which supports spermatogenesis. The Androxal clinical trials specifically measured sperm parameters and confirmed that sperm counts were maintained or improved with enclomiphene treatment. This is the primary advantage of both compounds over exogenous testosterone (TRT), which typically suppresses sperm production.
References
- Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744.
- Huijben, M., et al. (2022). Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis. Andrology, 10(3), 451-469.
- Kaminetsky, J., et al. (2013). Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in hypogonadal men with secondary hypogonadism. Journal of Urology, 189(6), 2221-2228.
- Wiehle, R.D., et al. (2014). Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertility and Sterility, 101(5), 1396-1402.
- Kim, E.D., et al. (2017). Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone. BJU International, 117(4), 677-685.
- Katz, D.J., et al. (2012). Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. Journal of Sexual Medicine, 9(6), 1659-1666.
- Guay, A.T., et al. (2003). Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction. International Journal of Impotence Research, 15, 156-165.
- Krzastek, S.C., et al. (2019). Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. Journal of Urology, 202(5), 1029-1035.
- Samplaski, M.K., et al. (2014). Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertility and Sterility, 101(1), 64-69.
- Taylor, F. & Levine, L. (2010). Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism. Journal of Sexual Medicine, 7(1), 269-276.
- Wu, F.C.W. & Sung, J.M. (2024). SERMs in male hypogonadism: current perspectives and future directions. Pharmaceuticals, 17(2), 118.
- Repros Therapeutics Inc. (2016). Form 10-K Annual Report. U.S. Securities and Exchange Commission.
Looking for Clomid (Clomiphene Citrate) 100 mg?
30 tablets, sealed blister packs, shipped from Canada.
Shop ClomidCanadian researchers can order both clomiphene citrate and enclomiphene from Elite Bio Supply. We ship to Toronto, Vancouver, Montreal, Edmonton, Ottawa, and every Canadian city with discreet domestic shipping.